Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Revenues: |
| Net Sales: Specialty HIV | 276.9 | 246.7 | 209.5 | | | | |
| Specialty HIV | 276.9 | 246.7 | 209.5 | | | | |
| Specialty Infusion | 63.7 | | | | | | |
| Total revenues | 340.7 | 246.7 | 209.5 | 123.1 | 60.1 | 42.5 | 27.5 |
| Revenue growth [+] | 38.1% | 17.7% | 70.2% | 104.9% | 41.4% | 54.8% | |
| Net Sales: Specialty HIV | 12.3% | 17.7% | | | | | |
| Specialty HIV | 12.3% | 17.7% | | | | | |
| Cost of goods sold | 279.9 | 211.4 | 178.9 | 103.2 | 53.2 | 37.0 | 23.3 |
| Gross profit | 60.8 | 35.3 | 30.6 | 19.9 | 6.9 | 5.5 | 4.2 |
| Gross margin | 17.8% | 14.3% | 14.6% | 16.1% | 11.5% | 12.9% | 15.2% |
| Selling, general and administrative | 35.5 | 26.7 | 24.2 | 18.4 | 9.2 | 7.7 | 4.8 |
| Other operating expenses | 0.5 | 0.6 | | | | | |
| EBITDA [+] | 24.7 | 7.9 | 6.5 | 3.4 | -1.5 | -1.6 | -0.3 |
| EBITDA growth | 211.3% | 22.6% | 88.1% | -325.6% | -6.1% | 538.1% | |
| EBITDA margin | 7.3% | 3.2% | 3.1% | 2.8% | -2.5% | -3.8% | -0.9% |
| Depreciation and amortization | 5.5 | 3.6 | 3.5 | 1.9 | 0.7 | 0.6 | 0.3 |
| EBIT [+] | 19.2 | 4.4 | 2.9 | 1.5 | -2.2 | -2.2 | -0.6 |
| EBIT growth | 339.5% | 48.6% | 94.6% | -167.4% | 0.6% | 291.3% | |
| EBIT margin | 5.6% | 1.8% | 1.4% | 1.2% | -3.7% | -5.3% | -2.1% |
| Non-recurring items [+] | 4.0 | | | | | 0.2 | -0.2 |
| Legal settlement | 4.0 | | | | | 0.2 | -0.2 |
| Interest income, net [+] | -2.5 | 0.8 | 1.3 | 1.1 | 0.2 | -0.2 | -0.1 |
| Interest expense | 2.9 | 0.0 | 0.1 | | | 0.2 | 0.1 |
| Interest income | 0.4 | 0.8 | 1.3 | 1.1 | 0.2 | | |
| Other income (expense), net | | | | -3.3 | -0.5 | | -0.5 |
| Pre-tax income | 12.8 | 5.2 | 4.2 | -0.7 | -2.5 | -2.7 | -1.0 |
| Income taxes | 5.2 | 1.9 | 1.0 | 0.3 | 0.1 | 0.0 | 0.0 |
| Tax rate | 41.1% | 37.0% | 24.0% | | | | |
| Earnings from continuing ops | 7.5 | 3.3 | 3.2 | -1.3 | | -2.7 | -1.0 |
| Earnings from discontinued ops | | | | -1.0 | -2.7 | | |
| Net income | 7.5 | 3.3 | 3.2 | -2.4 | -2.7 | -3.0 | -1.0 |
| Net margin | 2.2% | 1.3% | 1.5% | -1.9% | -4.5% | -7.0% | -3.8% |
| |
| Basic EPS [+] | $0.38 | $0.20 | $0.20 | ($0.16) | $0.00 | $0.00 | ($0.34) |
| Growth | 88.7% | 0.6% | -222.6% | | -100.0% | -99.7% | |
| Diluted EPS [+] | $0.34 | $0.19 | $0.19 | ($0.16) | $0.00 | $0.00 | ($0.34) |
| Growth | 76.2% | 1.9% | -215.3% | | -100.0% | -99.7% | |
| |
| Shares outstanding (basic) [+] | 19.8 | 16.2 | 16.0 | 8.2 | 3.1 | 3,100.0 | 3.1 |
| Growth | 22.2% | 1.6% | 94.5% | 164.6% | -99.9% | 99900.0% | |
| Shares outstanding (diluted) [+] | 22.3 | 17.0 | 17.0 | 8.2 | 3.1 | 3,100.0 | 3.1 |
| Growth | 30.9% | 0.3% | 106.9% | 164.6% | -99.9% | 99900.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|